SCHEMBL3064248

SCHEMBL3064248

O=C(CCl)Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 13/20 0.71
CYP3A4 P08684 5/20 0.71
CYP2C19 P33261 4/20 0.71
ADORA2A P29274 9/20 0.57
ADORA1 P30542 4/20 0.53
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 2/20 0.51
ADORA3 P0DMS8 3/20 0.48
GSK3B P49841 2/20 0.40
DYRK1A Q13627 2/20 0.40
CYP2D6 P10635 1/20 0.39
LMNA P02545 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3074836 0.89 ADORA2B (0.74) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3063823 0.88 ADORA2B (0.68) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3073782 0.86 ADORA2B (0.75) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3066499 0.86 ADORA2B (0.75) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3071385 0.84 ADORA2B (0.72) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
Las101057 SCHEMBL3075657 0.83 ADORA2B (1.00) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3063903 0.83 ADORA2B (0.71) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
Las101057 SCHEMBL29941566 0.83 ADORA2B (1.00) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3069437 0.82 GSK3B (0.64) ADORA2BCYP3A4CYP2C19ADORA2AADORA1
SCHEMBL3077266 0.81 ADORA2B (0.92) ADORA2BCYP3A4CYP2C19ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885CYP3A4 1868/4885CYP2C19 1218/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 ADORA2B 1/4885CYP3A4 857/4885CYP2C19 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.